Infliximab induces disease remission in patients with rheumatoid arthritis: Results from START clinical trial

被引：0
|
作者：
Yocum, D
Rahman, MU
Han, CL
Bala, M
Han, J
Westhovens, R
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] Centocor Inc, Horsham, PA USA
[3] Univ Hosp Gasthuisberg, Dept Rheumatol, Louvain, Belgium
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [31] Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study
    Chandrashekara, S.
    Shobha, Vineeta
    Dharmanand, B. G.
    Jois, Ramesh
    Kumar, Sharath
    Mahendranath, Kurugodu M.
    Haridas, Vikram
    Prasad, Shiva
    Singh, Yogesh
    Daware, Manisha A.
    Swamy, Anupama
    Subramanian, R.
    Somashekar, Srirama A.
    Shanthappa, Arun M.
    Anupama, K. R.
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (11) : 1977 - 1985
  • [32] Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept
    Haraoui, B
    Keystone, EC
    Thorne, JC
    Pope, JE
    Chen, I
    Asare, CG
    Leff, JA
    [J]. JOURNAL OF RHEUMATOLOGY, 2004, 31 (12) : 2356 - 2359
  • [33] Remission in patients with rheumatoid arthritis in routine clinical care
    Thonhofer, R
    Kriessmayr, M
    Gaugg, M
    Eder, S
    Erlacher, L
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 458 - +
  • [34] Impact of interstitial lung disease on clinical remission and unfavourable events of rheumatoid arthritis: results from the IORRA cohort
    Sugano, Eri
    Tanaka, Eiichi
    Inoue, Eisuke
    Honda, Suguru
    Abe, Mai
    Saka, Kumiko
    Sugitani, Naohiro
    Ochiai, Moeko
    Yamaguchi, Rei
    Ikari, Katsunori
    Harigai, Masayoshi
    [J]. RHEUMATOLOGY, 2024, 63 (04) : 1022 - 1029
  • [35] Comment on: Impact of interstitial lung disease on clinical remission of rheumatoid arthritis: results from the IORRA cohort: Reply
    Sugano, Eri
    Tanaka, Eiichi
    Inoue, Eisuke
    Harigai, Masayoshi
    [J]. RHEUMATOLOGY, 2024, 63 (04) : e134 - e135
  • [36] Natalizumab induces sustained response and remission in Crohn's patients after previous infliximab failure: Results from the encore trial
    Present, Daniel
    Feagan, Brian G.
    Fedorak, Richard N.
    Lashner, Bret
    Panaccione, Remo
    Rutgeerts, Paul
    Sandborn, William J.
    Spehlmann, Martina E.
    Tulassay, Zsolt
    Volfova, Mirostava
    Wolf, Douglas C.
    Targan, Stephan R.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A507 - A507
  • [37] PREDICTIVE MARKER FOR THE LONG-TERM DISCONTINUATION OF INFLIXIMAB IN RHEUMATOID ARTHRITIS WITH CLINICAL REMISSION
    Yamasaki, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 245 - 245
  • [38] Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study
    Uhlig, Till
    Lie, Elisabeth
    Norvang, Vibeke
    Lexberg, Ase Stavland
    Rodevand, Erik
    Kroll, Frode
    Kalstad, Synove
    Olsen, Inge C.
    Kvien, Tore K.
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (04) : 716 - 723
  • [39] Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
    Fleischmann, RM
    Cohen, SB
    Moreland, LW
    Schiff, M
    Mease, PJ
    Smith, DB
    Keenan, G
    Kremer, JM
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) : 1181 - 1190
  • [40] ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
    Pope, Janet E.
    Rampakakis, Emmanouil
    Movahedi, Mohammad
    Cesta, Angela
    Sampalis, John S.
    Bombardier, Claire
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345